Advertisement

More articles from Research Article

  • Downregulation of IL-8 sensitizes LCSCs toward treatment
    Deniz Cansen Kahraman, Tamer Kahraman, Rengul Cetin Atalay
    Molecular Cancer Therapeutics Jan 2019, molcanther.0004.2019; DOI: 10.1158/1535-7163.MCT-19-0004
  • Combination chemo- and immuno-therapy in PDAC
    Gulzar Ahmed, Gerardo G. Mackenzie, James Egan, Mansoor M. Amiji
    Molecular Cancer Therapeutics Jan 2019, molcanther.1046.2018; DOI: 10.1158/1535-7163.MCT-18-1046
  • SHP2-inhibition is effective at treating KRAS-mutant cancers
    Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Hengyu Lu, Bhavesh Pant, Matthew Shirley, Matthew J Meyer, Minying Pu, Joanne Lim, Michael Fleming, LeighAnn Alexander, Ali Farsidjani, Matthew J. LaMarche, Susan Moody, Serena J Silver, Giordano Caponigro, Darrin D. Stuart, Tinya J Abrams, Peter S. Hammerman, Juliet Williams, Jeffrey A. Engelman, Silvia Goldoni, Morvarid Mohseni
    Molecular Cancer Therapeutics Jan 2019, molcanther.0170.2019; DOI: 10.1158/1535-7163.MCT-19-0170
  • Preclinical comparison of BCMA CD3 Bispecific and ADCs
    Siler H. Panowski, Tracy C Kuo, Yi Zhang, Amy Chen, Tao Geng, Laura Aschenbrenner, Cris Kamperschroer, Edward Pascua, Wei Chen, Kathy Delaria, Santiago Farias, Marjorie Bateman, Russell G Dushin, Sherman M. Chin, Thomas J Van Blarcom, Yik Andy Yeung, Kevin C Lindquist, Allison G. Chunyk, Bing Kuang, Bora Han, Michael Mirsky, Ingrid Pardo, Bernard Buetow, Thomas G. Martin, Jeffrey L. Wolf, David Shelton, Arvind Rajpal, Pavel Strop, Javier Chaparro-Riggers, Barbra J Sasu
    Molecular Cancer Therapeutics Jan 2019, molcanther.0007.2019; DOI: 10.1158/1535-7163.MCT-19-0007
  • Efficacy of APE1/Ref-1 Redox inhibition in bladder cancer
    Melissa L. Fishel, Hanyu Xia, Jack McGeown, David W. McIlwain, May Elbanna, Ariel A. Craft, Hristos Z Kaimakliotis, George E. Sandusky, Chi Zhang, Roberto Pili, Mark R. Kelley, Travis J Jerde
    Molecular Cancer Therapeutics Jan 2019, molcanther.1166.2018; DOI: 10.1158/1535-7163.MCT-18-1166
  • Lenalidomide augments Eps8 peptide vaccine responses
    Xiaoling Xie, Yiran Chen, Yuxing Hu, Yanjie He, Honghao Zhang, Yuhua Li
    Molecular Cancer Therapeutics Jan 2019, molcanther.0424.2019; DOI: 10.1158/1535-7163.MCT-19-0424
  • PARP1 Inhibition Radiosensitizes Inflammatory Breast Cancer
    Anna R Michmerhuizen, Andrea M Pesch, Leah Moubadder, Benjamin C Chandler, Kari Wilder-Romans, Meleah Cameron, Eric Olsen, Dafydd G. Thomas, Amanda Zhang, Nicole Hirsh, Cassandra L Ritter, Meilan Liu, Shyam Nyati, Lori J Pierce, Reshma Jagsi, Corey Speers
    Molecular Cancer Therapeutics Jan 2019, molcanther.0520.2019; DOI: 10.1158/1535-7163.MCT-19-0520
  • FGF401 selectively targets FGF19+ hepatocellular tumors
    Andreas Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm, Robin A Fairhurst, Michael Kiffe, Dario Sterker, Mario Centeleghe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Heiko S Schadt, Philippe Couttet, Armin Wolf, Youzhen Wang, Patrizia Barzaghi-Rinaudo, Masato Murakami, Audrey Kauffmann, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Pascal Furet, Jutta Blank, Francesco Hofmann, William R. Sellers, Diana Graus Porta
    Molecular Cancer Therapeutics Jan 2019, molcanther.1291.2018; DOI: 10.1158/1535-7163.MCT-18-1291
  • Targeting DEPTOR in myeloma
    Mario I Vega, Yijiang Shi, Patrick Frost, Sara Huerta-Yepez, Gabriela Antonio-Andres, Rogelio Hernandez-Pando, Jihye Lee, Michael E Jung, Joseph F Gera, Alan Lichtenstein
    Molecular Cancer Therapeutics Jan 2019, molcanther.0115.2019; DOI: 10.1158/1535-7163.MCT-19-0115
  • Preclinical Activity of novel HER3-ADC in Colorectal Cancer
    Shigehiro Koganemaru, Yasutoshi Kuboki, Yoshikatsu Koga, Takashi Kojima, Mayumi Yamauchi, Naoyuki Maeda, Takashi Kagari, Kenji Hirotani, Masahiro Yasunaga, Yasuhiro Matsumura, Toshihiko Doi
    Molecular Cancer Therapeutics Jan 2019, molcanther.0452.2019; DOI: 10.1158/1535-7163.MCT-19-0452

Pages